Please login to the form below

Not currently logged in

Intermune supports awareness efforts for IPF

Last week's IPF World Week saw the global patient community unite

IPF World Week 2013 IntermuneBiotech firm Intermune last week lent its backing to IPF World Week to support the awareness campaign for idiopathic pulmonary fibrosis (IPF).

The rare progressive and fatal lung disease is characterised by the formation of scar tissue within the lungs and affects approximately five million people worldwide.

The fundamental aim of IPF World Week is to lessen patients' isolation and fear by demonstrating that there is a growing community of support.

Last week the event saw healthcare professionals, advocacy groups, patients and their families come together to call for an integrated approach to tackling the disease and supporting those affected.

Specifically IPF World Week is working towards creating a national and international support network for IPF patients, raising awareness by informing, training and guiding stakeholders, and offering support and tools to patients and their families.

This year's theme for the Week was 'Breath of Hope' and representative images were selected by European, American and Canadian IPF associations by means of public competitions, with one of the winning images - from the Irish Lung Fibrosis Association - pictured above.

“The two winning images represent support across generations, using soap bubbles as the symbol chosen to promote IPF awareness,” said Rosalba Mele, president of patient association Ama Fuoridalbuio.

In Europe, some 100 initiatives took place in IPF centres of excellence, while a number of US initiatives ran throughout September, driven by Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF).

“It's the role of physicians, patient advocacy groups and medical companies to raise awareness of conditions in order to help and provide the tools for individuals with the disease to cope better,” said Professor Jim Egan, director of Ireland's National Advanced Lung Disease Programme.

Patients were also encouraged to embrace digital advances, particularly in the form of online communities such as RareConnect and IPFWorld.

Article by
Tara Craig

1st October 2013

From: Marketing, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...